Συγγραφείς:
McCarthy, A.
Kerr, M.
Abadie, E.
Chibout, S.-D.
Imbert, G.
Cohen, N.
Drakoulis, N.
Knudsen, L.E.
Flamion, B.
Hashimoto, L.
Verhoofstad, W.
Kreutz, G.
McHale, D.
Mitchell, T.
Papaluca Amati, M.
Roberts, R.
Shaw, P.
Stuerzebecher, C.S.
Townend, D.
Λέξεις-κλειδιά:
alosetron; antidiabetic agent; atomoxetine; BCR ABL protein; cytochrome P450 2D6; epidermal growth factor receptor 2; imatinib; serotonin transporter; serotonin uptake inhibitor; trastuzumab, article; attention deficit disorder; breast cancer; chronic myeloid leukemia; clinical study; clinical trial; constipation; depression; diabetes mellitus; diagnostic test; drug absorption; drug approval; drug design; drug efficacy; drug industry; drug metabolism; drug safety; enteritis; European Union; fluorescence in situ hybridization; food and drug administration; health care policy; health program; human; immunohistochemistry; ischemic colitis; legal aspect; medical decision making; medical ethics; medical research; medical society; pharmacogenetics; postmarketing surveillance; social aspect; workshop, Clinical Trials; Decision Making; Drug Design; Drug Industry; Humans; Pharmacogenetics; Product Surveillance, Postmarketing
